Patents by Inventor Robert Akita

Robert Akita has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20130209495
    Abstract: Antibodies are disclosed which bind to ErbB3 protein and further possess any one or more of the following properties: an ability to reduce heregulin-induced formation of an ErbB2-ErbB3 protein complex in a cell which expresses ErbB2 and ErbB3; the ability to increase the binding affinity of heregulin for ErbB3 protein; and the characteristic of reducing heregulin-induced ErbB2 activation in a cell which expresses ErbB2 and ErbB3.
    Type: Application
    Filed: March 22, 2013
    Publication date: August 15, 2013
    Applicant: GENENTECH, INC.
    Inventors: Robert Akita, Mark Sliwkowski
  • Publication number: 20120014969
    Abstract: Antibodies are disclosed which bind to ErbB3 protein and further possess any one or more of the following properties: an ability to reduce heregulin-induced formation of an ErbB2-ErbB3 protein complex in a cell which expresses ErbB2 and ErbB3; the ability to increase the binding affinity of heregulin for ErbB3 protein; and the characteristic of reducing heregulin-induced ErbB2 activation in a cell which expresses ErbB2 and ErbB3.
    Type: Application
    Filed: July 12, 2011
    Publication date: January 19, 2012
    Inventors: Robert Akita, Mark Sliwkowski
  • Publication number: 20080124334
    Abstract: Antibodies are disclosed which bind to ErbB3 protein and further possess any one or more of the following properties: an ability to reduce heregulin-induced formation of an ErbB2-ErbB3 protein complex in a cell which expresses ErbB2 and ErbB3; the ability to increase the binding affinity of heregulin for ErbB3 protein; and the characteristic of reducing heregulin-induced ErbB2 activation in a cell which expresses ErbB2 and ErbB3.
    Type: Application
    Filed: November 20, 2007
    Publication date: May 29, 2008
    Inventors: Robert Akita, Mark Sliwkowski
  • Patent number: 7285649
    Abstract: Antibodies are disclosed which bind to ErbB3 protein and further possess any one or more of the following properties: an ability to reduce heregulin-induced formation of an ErbB2-ErbB3 protein complex in a cell which expresses ErbB2 and ErbB3; the ability to increase the binding affinity of heregulin for ErbB3 protein; and the characteristic of reducing heregulin-induced ErbB2 activation in a cell which expresses ErbB2 and ErbB3.
    Type: Grant
    Filed: April 4, 2001
    Date of Patent: October 23, 2007
    Assignee: Genentech, Inc.
    Inventors: Robert Akita, Mark Sliwkowski
  • Publication number: 20070122407
    Abstract: Antibodies are disclosed which bind to ErbB3 protein and further possess any one or more of the following properties: an ability to reduce heregulin-induced formation of an ErbB2-ErbB3 protein complex in a cell which expresses ErbB2 and ErbB3; the ability to increase the binding affinity of heregulin for ErbB3 protein; and the characteristic of reducing heregulin-induced ErbB2 activation in a cell which expresses ErbB2 and ErbB3.
    Type: Application
    Filed: September 25, 2006
    Publication date: May 31, 2007
    Inventors: Robert Akita, Mark Sliwkowski
  • Publication number: 20050136494
    Abstract: Antibodies are disclosed which bind to ErbB3 protein and further possess any one or more of the following properties: an ability to reduce heregulin-induced formation of an ErbB2-ErbB3 protein complex in a cell which expresses ErbB2 and ErbB3; the ability to increase the binding affinity of heregulin for ErbB3 protein; and the characteristic of reducing heregulin-induced ErbB2 activation in a cell which expresses ErbB2 and ErbB3.
    Type: Application
    Filed: February 4, 2005
    Publication date: June 23, 2005
    Inventors: Robert Akita, Mark Sliwkowski
  • Publication number: 20020064805
    Abstract: Antibodies are disclosed which bind to ErbB3 protein and further possess any one or more of the following properties: an ability to reduce heregulin-induced formation of an ErbB2-ErbB3 protein complex in a cell which expresses ErbB2 and ErbB3; the ability to increase the binding affinity of heregulin for ErbB3 protein; and the characteristic of reducing heregulin-induced ErbB2 activation in a cell which expresses ErbB2 and ErbB3.
    Type: Application
    Filed: April 4, 2001
    Publication date: May 30, 2002
    Applicant: Genentech, Inc.
    Inventors: Robert Akita, Mark Sliwkowski
  • Patent number: 5968511
    Abstract: Antibodies are disclosed which bind to ErbB3 protein and further possess any one or more of the following properties: an ability to reduce heregulin-induced formation of an ErbB2-ErbB3 protein complex in a cell which expresses ErbB2 and ErbB3; the ability to increase the binding affinity of heregulin for ErbB3 protein; and the characteristic of reducing heregulin-induced ErbB2 activation in a cell which expresses ErbB2 and ErbB3.
    Type: Grant
    Filed: March 25, 1997
    Date of Patent: October 19, 1999
    Assignee: Genentech, Inc.
    Inventors: Robert Akita, Mark Sliwkowski